. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389 1. Classification of Atypical Antipsychotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391 2. Clinical Effect of Atypical Antipsychotics . . . . . . . . . . . . . . ...

Objective Human serum paraoxonase (PON1) prevents lipids from peroxidation and functions as an antioxidant mechanism. Malonyldialdehyde (MDA) is the final product of lipid peroxidation and can be used as an indicator of oxidative stress. The aim of this study was to investigate PON1, MDA, and arylesterase (ARY) levels in schizophrenic patients who are taking typical, atypical, or combined (typi...

Treatment-emergent diabetes mellitus (DM) has been described for conventional and atypical antipsychotics. In our study, antipsychotic prescription claims from AdvancePCS's database were used to identify patients starting antipsychotic monotherapy. The relative risk of developing DM was determined using prescription claims for antidiabetic agents in the following cohorts: AdvancePCS general pat...

BACKGROUND The role of antipsychotics in influencing mortality of patients with mental disorders is still unexplained. OBJECTIVE The aim of this study was to determine mortality rates of patients treated with atypical and typical antipsychotics and to compare these data with the mortality rates for the general population. METHODS The study was based on the 2008-2012 prescription drug reimbu...

The development of atypical (or second generation) antipsychotics has offered people with schizophrenia more treatment options. Atypical antipsychotics are judged to be more effective in alleviating symptoms of the illness and to be associated with fewer side-effects in most patients. They are more expensive than the earlier class of antipsychotics, so-called typical antipsychotics, but doubt r...

Second generation antipsychotics are associated with weight gain and other metabolic side effects (1). Among the atypical antipsychotics, treatment with olanzapine has been found to worsen the lipid profile (2). Atypical antipsychotics also increase the risk of developing metabolic syndrome (3, 4). The baseline prevalence of diabetes maybe two to three folds higher in patients with schizophreni...

BACKGROUND Atypical antipsychotics are increasingly used for treatment of mental illnesses like schizophrenia and bipolar disorder, and considered to have fewer extrapyramidal effects than older antipsychotics. METHODS We examined efficacy in randomised trials of bipolar disorder where the presenting episode was either depression, or manic/mixed, comparing atypical antipsychotic with placebo ...

Background: Antipsychotics have been used for many years for the treatment of neurological disorders, and the application of antipsychotics in the elderly have increased in frequency over the past few years. The absolute benefit of typical as well as atypical antipsychotics have come into question as their safety in elderly population is not seem to be in sync with their theoretical assessments...

BACKGROUND The gold standard pharmacological agents used to treat schizophrenia and bipolar disorder in adults are antipsychotics. Atypical or second-generation antipsychotics have superseded or used as alternatives to typical first-generation antipsychotics due to better tolerability and safety profile. However the efficacy and safety of these drugs are severely limited in pregnancy and/or wom...

Despite a large number of neuroimaging studies in schizophrenia reporting subtle brain abnormalities, we do not know to what extent such abnormalities reflect the effects of antipsychotic treatment on brain structure. We therefore systematically reviewed cross-sectional and follow-up structural brain imaging studies of patients with schizophrenia treated with antipsychotics. 30 magnetic resonan...